A lone biotech braves the bone-dry IPO fore­cast, seek­ing to go pub­lic amidst a bar­ren land­scape

Just two months af­ter putting to­geth­er a pri­vate fund­ing round, a Cal­i­for­nia biotech is head­ed to Nas­daq.

AN2 Ther­a­peu­tics filed its S-1 pa­per­work on Fri­day, pen­cil­ing in a $75 mil­lion raise to get things go­ing. The com­pa­ny is at­tempt­ing to make the pub­lic leap as the biotech sec­tor con­tin­ues to reel from a bear mar­ket that’s seen small- and large-cap firms take heavy stock mar­ket beat­ings and shuf­fle their C-suites.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER